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Aim Anaemia is common in heart failure and associated with worse outcomes. We examined the effect of dapagliflozin on
correction of anaemia in patients with heart failure (HF) and reduced ejection fraction in DAPA-HF. We also analysed
the effect of dapagliflozin on outcomes, according to anaemia status at baseline.
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Methods
and results
Anaemia was defined at baseline as a haematocrit <39% in men and <36% in women. Resolution of anaemia was
defined as two consecutive haematocrit measurements above these thresholds at any time during follow-up. The
primary outcome was a composite of worsening HF (hospitalization or urgent visit requiring intravenous therapy) or
cardiovascular death. Of the 4744 patients randomized in DAPA-HF, 4691 had a haematocrit available at baseline, of
which 1032 were anaemic (22.0%). The rate of the primary outcome was higher in patients with anaemia (16.1 per
100 person-years) compared with those without (12.9 per 100 person-years). Anaemia was corrected in 62.2% of
patients in the dapagliflozin group, compared with 41.1% of patients in the placebo group. The effect of dapagliflozin
on the primary outcome was consistent in anaemic compared with non-anaemic patients [hazard ratio (HR) 0.68,
95% confidence interval (CI) 0.52–0.88 vs. HR 0.76, 95% CI 0.65–0.89; interaction P = 0.44]. Similar findings were
observed for cardiovascular death, HF hospitalization, and all-cause mortality. Patients with resolution of anaemia
had better outcomes than those in which anaemia persisted.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Patients with anaemia had worse outcomes in DAPA-HF. Dapagliflozin corrected anaemia more often than placebo
and improved outcomes, irrespective of anaemia status at baseline.
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Keywords Heart failure with reduced ejection fraction • Anaemia • Clinical trials • Sodium–glucose
co-transporter 2 inhibitor
Introduction
Anaemia is a common finding in heart failure although it was not
recognized as such until the turn of the century.1,2 Its aetiology
is complex, probably reflecting renal impairment, inflammation,
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iron deficiency and treatment with angiotensin-converting enzyme
inhibitors, among other factors.1 Patients with anaemia generally
have worse symptoms, greater functional impairment, higher rates
of hospital admission and shorter survival than those without.3
Anaemia remains prognostically important, even when other
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predictive variables are accounted for.4 Why anaemia is an inde-
pendent predictor of worse outcomes is not fully understood.
However, given that heart failure, physiologically, is a syndrome
in which oxygen delivery to the metabolizing tissues is insuffi-
cient, it is clear why anaemia might be an exacerbating factor.5
There have been attempts to correct anaemia in heart failure,
using different approaches.6–10 The erythropoiesis-stimulating dar-
bepoetin did not reduce the risk of death or hospitalization for
heart failure but did improve quality of life.6 Several studies have
shown that intravenous iron improves symptoms, quality of life and
functional capacity.7–9 The Study to Compare Ferric Carboxymal-
tose With Placebo in Patients With Acute Heart Failure and Iron
Deficiency (AFFIRM-AHF) reported that in hospitalized patients
stabilized from an episode of worsening heart failure, the admin-
istration of intravenous ferric carboxymaltose reduced the risk
of rehospitalization for heart failure compared with placebo and
ongoing trials will provide further data regarding the long-term
effects of intravenous iron on morbidity and mortality in heart
failure.10
Recently, sodium–glucose co-transporter 2 inhibitors (SGLT2i)
have been shown to increase haematocrit.11–13 While, initially,
this was thought simply to reflect volume contraction due to
diuresis, there is growing evidence that these drugs may stim-
ulate erythropoiesis by suppressing hepcidin and increasing
erythropoietin.14–18 The placebo-controlled Dapagliflozin And
Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF)
provides a unique opportunity to examine whether a SGLT2i cor-
rects anaemia in patients with heart failure and reduced ejection
fraction (HFrEF) and the impact of this treatment on symptoms,
quality of life, hospitalization and mortality.12
Methods
DAPA-HF was a prospective, randomized, double-blind,
placebo-controlled trial in patients with HFrEF, which evaluated
the efficacy and safety of dapagliflozin 10 mg once daily, compared
with matching placebo, added to standard care.12,19,20 Ethics commit-
tees at each participating institution approved the protocol, and all
patients gave written informed consent.
Study patients
Men and women aged ≥18 years in New York Heart Association
(NYHA) functional class II–IV, with a left ventricular ejection fraction
≤40% and a modesty elevated concentration of N-terminal pro-B-type
natriuretic peptide (NT-proBNP) concentration, were eligible if, in the
view of the investigator, they were optimally treated with pharmaco-
logical and device therapy, according to local guidelines. Key exclu-
sion criteria included: symptoms of hypotension or systolic blood
pressure <95 mmHg, estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m2, type 1 diabetes mellitus, and another condition
likely to prevent patient participation in the trial or greatly limit life
expectancy. There was no specific exclusion related to anaemia or
haemoglobin/haematocrit. Concomitant use of an open-label SGLT2i




















































































.. Measurement of haematocrit,
haemoglobin and definition of anaemia
Haematocrit was measured at baseline, as well as 14 days, 2 months
and 4 months after randomization, and four monthly thereafter.
Haemoglobin was measured at baseline and at end of study but not
routinely after randomization. All measurements were performed in
a central laboratory. Anaemia was defined at baseline as a haema-
tocrit <39% in men and <36% in women.21 Correction of anaemia
after randomization was defined as two consecutive haematocrit mea-
surements above these thresholds at any time during follow-up. For
the purposes of sensitivity analyses examining the association between
anaemia and outcomes, anaemia was also defined using sex-specific
baseline haemoglobin thresholds (male <130 g/L and female <120 g/L).
Other laboratory variables (including creatinine and NT-proBNP) and
physiological measurements (weight, blood pressure) were made at
baseline and during follow-up.
Trial outcomes
The primary outcome was the composite of an episode of worsen-
ing heart failure or cardiovascular death, whichever occurred first. An
episode of worsening heart failure was either an unplanned hospitaliza-
tion or an urgent visit resulting in intravenous therapy for heart failure.
The first of the secondary outcomes was the composite of heart failure
hospitalization or cardiovascular death. The additional secondary out-
comes were: total number of recurrent heart failure hospitalizations
(including repeat admissions) and cardiovascular deaths; change from
baseline to 8 months in the total symptom score of the Kansas City
Cardiomyopathy Questionnaire (KCCQ-TSS) using a scale from 0 to
100, with a higher score indicating fewer symptoms and a ≥5 point
change considered clinically meaningful22; the incidence of a composite
worsening renal function outcome (there were few of these events);
and death from any cause. All cardiovascular endpoints and deaths
were adjudicated by an independent, blinded, committee.
For the purposes of this analysis, we examined the effect of
dapagliflozin, compared to placebo, on the primary composite out-
come, the individual components of cardiovascular death and wors-
ening heart failure events (defined as hospitalization for heart failure
or an urgent outpatient visit requiring use of intravenous therapy) and
the pre-specified secondary endpoints of total events and death from
any cause. We also examined the additional effect on KCCQ overall
summary score (OSS) and clinical summary score (CSS).
Statistical analysis
Baseline characteristics were compared between anaemia groups by
using the two-sample t test and Wilcoxon rank-sum test for normal
and non-normal continuous variables and the χ2 test for categori-
cal variables. The cumulative incidence of the primary endpoint by
treatment assignment in the anaemia subgroups was analysed by
means of the Kaplan–Meier method and plotted graphically. The
effect of dapagliflozin compared to placebo on each outcome was
examined by means of hazard ratio (HR) and 95% confidence intervals
(CI) derived from Cox proportional-hazards models adjusted for a
history of hospitalization for heart failure and treatment assignment
and stratified by baseline diabetes status. For the anaemia yes/no
subgroup analyses, an interaction test was performed to assess for any
modification of treatment effect by anaemia status. The relationship
between anaemia at baseline and subsequent outcomes was examined
by means examined by means of HR and 95% CI derived from Cox
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proportional-hazards models adjusted for a history of hospitalization
for heart failure and treatment assignment. For the endpoint of
all-cause mortality, no adjustment for a history of hospitalization for
heart failure was performed. The effect on the composite endpoint of
recurrent (first and total HF hospitalizations) and cardiovascular death
was examined using a semiparametric proportional-rates model.23 A
second analysis was performed with further adjustment for age, heart
rate, systolic blood pressure, body mass index, ischaemic aetiology
of heart failure, left ventricular ejection fraction, NYHA functional
classification, NT-proBNP, atrial fibrillation, mineralocorticoid recep-
tor antagonist use and eGFR. The relative hazard of death from any
cause and cardiovascular causes following reversal of anaemia was
examined in a Cox proportional-hazards model where an indicator of
a resolution of anaemia was entered into the model as a time-updated
covariate (with follow-up time starting at randomization). The period
at risk prior to resolution of anaemia was attributed to the group
who had persisting anaemia in order to calculate incidence rates
which reflect patients’ time-updated event status. The model was
repeated with adjustment for randomized treatment, history of heart
failure hospitalization, age, sex, heart rate, systolic blood pressure,
body mass index, ischaemic aetiology of heart failure, left ventricular
ejection fraction, NYHA functional classification, NT-proBNP, atrial
fibrillation, and eGFR and diabetes status. This analysis was repeated
for the endpoint of recurrent heart failure hospitalizations and cardio-
vascular death using using a semiparametric proportional-rates model.
Changes in vital signs and laboratory values were analysed using a
mixed model for repeated measurements (adjusted for baseline values,
visit, randomized treatment and interaction of treatment and visit with
a random intercept and slope per patient) and the between-treatment
group difference at 8 months following randomization are presented
by subgroup as least square means difference and 95% CI. In patients
randomized to dapagliflozin, the correlation between change in haema-
tocrit and other laboratory measures and vital signs at visit 3 (14 days)
and visit 6 (8 months) was examined using Pearson’s correlation
coefficient. The effect of dapagliflozin on the reversal or development
of anaemia during follow-up was examined with a logistic regression
model with randomized treatment as the only independent variable.
A sensitivity analysis was performed using a mixed-effects logistic
regression model with correction of anaemia occurring at any time
during follow-up defined using the haematocrit thresholds detailed
previously. The treatment effect on the proportion of patients with a
clinically meaningful improvement (≥5 point increase) or deterioration
(≥5 point decrease) in KCCQ scores is presented as an odds ratios
(OR) with 95% CI calculated using methods described previously.22 All
analyses were performed using Stata version 16 (Stata Corp., College
Station, TX, USA) and SAS, version 9.4 (SAS Institute, Cary, NC,
USA). A P-value <0.05 was considered statistically significant.
Results
Of the 4744 patients randomized in DAPA-HF, 4691 had a haema-
tocrit available at baseline and 1032 of these participants were
anaemic (22.0%). The distribution of baseline haematocrit and
haemoglobin by sex is shown in online supplementary Figure S1.
The proportion of patients with anaemia in the dapagliflozin and
placebo groups did not differ significantly [535/2346 (22.8%) vs.
497/2345 (21.2%)]. In a sensitivity analysis, using sex-specific base-
line haemoglobin thresholds (male <130 g/L and female <120 g/L),
the proportion of patients with anaemia was 27.7% and this was



















































































.. Patient characteristics according
to anaemia status at baseline
The baseline characteristics of patients according to their anaemia
status are shown in Table 1. Compared to those who were not
anaemic, patients who were anaemic were older, more likely to
be male and had a lower mean systolic blood pressure, higher
NT-proBNP level, and worse kidney function. A history of coro-
nary heart disease, diabetes and prior heart failure hospitalization
was more common among patients with anaemia, compared to
those without anaemia. NYHA functional class and KCCQ-TSS did
not differ significantly between those with and without anaemia.
The prescription of key treatments was similar in the two groups,
except for use of a mineralocorticoid receptor antagonist, which
was less in individuals with anaemia. During follow-up, a small
number of patients received treatments for iron deficiency and/or
anaemia (including patients taking these at the time of randomiza-
tion); intravenous iron in 12 (0.5%) and 13 (0.5%), oral iron in 123
(5.2%) and 117 (4.9%), vitamin B12 in 72 (3.0%) and 71 (3.0%),
and folic acid in 51 (2.1%) and 56 (2.4%) patients randomised to
dapagliflozin and placebo, respectively.
Cardiovascular outcomes according
to anaemia status at baseline
The cumulative incidence of the primary composite endpoint and
the secondary morbidity/mortality endpoints are shown in Figure 1
and Table 2. For each of these, the risk was higher in individuals
with anaemia than in those without, in unadjusted analyses. After
adjustment, only worsening heart failure and not death remained
significantly higher in anaemic patients. In a sensitivity analysis using
a haemoglobin-based definition of anaemia, in adjusted analyses
anaemia was associated with a significantly higher risk of the pri-
mary composite endpoint, worsening heart failure, all-cause mor-
tality and the composite endpoint of total heart failure hospitaliza-
tions and cardiovascular death (online supplementary Table S1).
Effects of dapagliflozin on haematocrit
and anaemia status after randomization
Change in haematocrit from baseline is shown in Figure 2. The time
course and magnitude of the change with dapagliflozin was similar
in patients with and without anaemia. The mean placebo-corrected
increase at 8 months was 2.38 (1.93 to 2.83)% in participants with
anaemia and 2.44 (2.21 to 2.67)% in those without anaemia (inter-
action P = 0.88) (Table 3). The proportion of patients who were
anaemic at baseline and experienced a persistent rise in haema-
tocrit into the non-anaemic range was 62.2% in the dapagliflozin
group and 41.1% in the placebo group, giving an OR for anaemia
correction of 2.37 (95% CI 1.84–3.04; P < 0.001). A similar result
was seen in a sensitivity analysis using a mixed-effects logistic
regression model (OR 3.06, 95% CI 1.95–4.80; P < 0.001). In a
further sensitivity analysis in patients who were anaemic at baseline
according to standard sex-specific haemoglobin thresholds, using
the last recorded haemoglobin measurement during follow-up the
OR for dapagliflozin vs. placebo for correction of anaemia was
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Age, years 65.4±11.0 69.8± 9.7 <0.001
Sex <0.001
Female 893 (24.4) 200 (19.4)
Male 2766 (75.6) 832 (80.6)
Racea <0.001
White 2623 (71.7) 673 (65.2)
Asian 826 (22.6) 284 (27.5)
Black 153 (4.2) 63 (6.1)
Other 57 (1.6) 12 (1.2)
Region <0.001
Asia/Pacific 826 (22.6) 284 (27.5)
Europe 1745 (47.7) 408 (39.5)
North America 444 (12.1) 227 (22.0)
South America 654 (17.9) 121 (11.7)
NYHA functional class 0.13
II 2440 (66.7) 718 (69.6)
III 1182 (32.3) 308 (29.8)
IV 37 (1.0) 6 (0.6)
Heart rate, bpm 71.7±11.7 70.6±11.4 0.008
Systolic blood pressure, mmHg 122.3±16.2 120.2±16.5 <0.001
Left ventricular ejection fraction, % 31.0± 6.9 31.5± 6.6 0.036
NT-proBNP, pg/mL 1350.9 [820.5–2442.2] 1840.0 [1042.8–3314.9] <0.001
KCCQ-TSS 77.1 [58.3–91.7] 78.1 [60.4–91.7] 0.39
Haemoglobin (g/L) 140.6±13.4 117.7±12.2 <0.001
Body mass index, kg/m2 28.4± 6.0 27.2± 5.9 <0.001
Principal cause of heart failure 0.033
Ischaemic 2031 (55.5) 619 (60.0)
Non-ischaemic 1331 (36.4) 333 (32.3)
Unknown 297 (8.1) 80 (7.8)
Medical history
Hospitalization for heart failure 1702 (46.5) 510 (49.4) 0.099
Atrial fibrillation 1408 (38.5) 391 (37.9) 0.73
Type 2 diabetesb 1433 (39.2) 526 (51.0) <0.001
Prior MI 1598 (43.7) 476 (46.1) 0.16
Prior PCI 1229 (33.6) 384 (37.2) 0.031
Prior CABG 559 (15.3) 231 (22.4) <0.001
eGFR, mL/min/1.73 m2 67.6±19.2 59.3±18.6 <0.001
eGFR rate <60 mL/min/1.73 m2 1355 (37.0) 550 (53.3) <0.001
Device therapy
Implantable cardioverter-defibrillatorc 945 (25.8) 285 (27.6) 0.25
Cardiac resynchronization therapyd 263 (7.2) 90 (8.7) 0.099
Heart failure medication at randomization visit
Diuretic 3070 (83.9) 893 (86.5) 0.039
ACE-inhibitor or ARB 3072 (84.0) 829 (80.3) 0.006
Sacubitril/valsartan 385 (10.5) 123 (11.9) 0.20
Beta-blocker 3519 (96.2) 989 (95.8) 0.62
MRA 2653 (72.5) 687 (66.6) <0.001
Digitalis 706 (19.3) 158 (15.3) 0.004
Antiplatelet 1947 (53.2) 610 (59.1) <0.001
Anticoagulant 1531 (41.8) 416 (40.3) 0.38
Data presented as mean (standard deviation), n (%), or median [interquartile range].
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; KCCQ-TSS, Kansas City Cardiomyopathy
Questionnaire total symptom score - range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure. A score of ≥75 is considered to reflect
satisfactory health status; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention.
aPercentages may not total 100 because of rounding.
b993 patients (41.8%) in the dapagliflozin group and 990 in the placebo group (41.8%) had a history of diabetes at baseline. An additional 82 patients in the dapagliflozin group and 74 in the placebo group
had previously undiagnosed diabetes defined as a glycated haemoglobin level of ≥6.5% (≥48 mmol/mol) measured in a central laboratory at both screening and randomization.
cEither implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.
dCardiac resynchronization therapy with or without a defibrillator.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Effect of dapagliflozin compared with placebo on cardiovascular outcomes according to presence of anaemia. Kaplan–Meier
estimates of the cumulative incidence of: (A) primary composite endpoint [time to first worsening heart failure event, defined as a worsening
heart failure event (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or death from cardiovascular causes];
(B) cardiovascular death; (C) worsening heart failure event; (D) all-cause mortality.
2.09 (95% CI 1.61–2.71; P < 0.001). Conversely, the proportion
of patients who were not anaemic at baseline and experienced a
decrease in haematocrit into the anaemic range that persisted was
4.5% in the dapagliflozin group and 11.0% in the placebo group, giv-
ing an OR for development of anaemia of 0.38 (95% CI 0.29–0.49;
P < 0.001).
Changes in weight, sodium, urea (blood urea nitrogen), crea-
tinine, urea-to-creatinine ratio, blood pressure, and NT-proBNP
from baseline are shown in Table 3. The magnitude of these changes
was similar in patients with and without anaemia at baseline. At visit
3 (14 days after randomization), there were significant correlations
(P < 0.001 for all) between change in weight, eGFR, creatinine
and urea, and change in haematocrit in patients randomized to
dapagliflozin, but all correlations were weak with r values between





















.. 8 months, no laboratory or physiological variable correlated sig-
nificantly with haematocrit.
Effects of dapagliflozin on cardiovascular
outcomes according to baseline anaemia
status
The effects of dapagliflozin, compared with placebo, in patients with
and without anaemia, are shown in Figure 1 and Table 4.
The beneficial effect of dapagliflozin, compared with placebo,
on the primary endpoint (HR 0.74, 95% CI 0.65–0.85 in overall
trial) was consistent in patients with (HR 0.68, 95% CI 0.52–0.88)
and without (HR 0.76, 95% CI 0.65–0.89) anaemia (interaction
P = 0.44). This beneficial effect was consistent across the range of
haematocrit and haemoglobin levels at baseline when examined as a
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Continued
continuous variable (online supplementary Figure S2). In those with
anaemia at baseline, there was no modification of the treatment
effect of dapagliflozin on the primary endpoint whether patients
had resolution (HR 0.73, 95% CI 0.46–1.14) or persistence (HR
0.84, 95% CI 0.60–1.18) of anaemia (interaction P = 0.66).
In general, the effect of dapagliflozin on each of the components
of the primary outcome and the secondary outcomes was similar
both for individuals with and without anaemia (Figure 1 and Table 4).
Because of the much higher event rate in anaemic patients, the
absolute risk reductions with dapagliflozin, compared with placebo,
were larger than in non-anaemic patients, i.e. 6.2 vs. 3.5 per 100
person-years for the primary composite outcome, 2.6 vs. 1.1 per
100 person-years for cardiovascular death and 5.1 vs. 2.5 per 100
person-years for worsening heart failure.
Eight months after randomization, the mean increase (improve-
ment) in KCCQ-TSS with dapagliflozin, compared with placebo,

























.. compared to those without (+2.5, 95% CI 1.1–3.8), although this
difference between anaemic and non-anaemic patient subgroups
was not statistically significant (interaction P = 0.34) (Table 5). A
similar picture was seen for KCCQ-CSS and KCCQ-OSS.
Outcomes associated with resolution vs.
persistence of anaemia during follow-up
When resolution of anaemia was considered a time-updated
covariate, the rate of the composite outcome of total (including
recurrent) heart failure hospitalizations and cardiovascular death
in patients with anaemia at baseline who had resolution of anaemia
(n = 537, 52%), irrespective of treatment allocation, was lower than
in those who had persistence of anaemia during follow-up (n = 495,
48%): 19.7 (95% CI 16.2–23.9) per 100 person-years vs. 27.7 (95%
CI 24.5–31.3) per 100 person-years, giving an adjusted HR of this
outcome for resolution vs. persistence of anaemia of 0.75 (95% CI
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Outcomes according to anaemia status defined using haematocrit thresholds
Outcome Event rate per 100 person-years Unadjusted HR
(95% CI)
Adjusted





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite endpoint 16.1 (14.1–18.4) 12.9 (11.9–13.9) 1.20 (1.03–1.40); P = 0.020 1.06 (0.91–1.25); P = 0.45
Cardiovascular death 8.7 (7.3–10.3) 6.9 (6.2–7.6) 1.23 (1.00–1.50); P = 0.047 0.99 (0.80–1.23); P = 0.94
Worsening HF event 11.3 (9.6–13.2) 7.9 (7.1–8.7) 1.35 (1.12–1.63); P = 0.002 1.22 (1.00–1.48); P = 0.046
All-cause mortality 10.4 (8.9–12.2) 8.3 (7.6–9.1) 1.23 (1.02–1.48); P = 0.030 0.99 (0.82–1.20); P = 0.93
Total HF hospitalizations and
cardiovascular deatha
24.5 (22.1–27.2) 17.5 (16.4–18.6) 1.34 (1.13–1.59); P = 0.001 1.14 (0.96–1.36); P = 0.14
CI, confidence interval; HF, heart failure; HR, hazard ratio.
HR presented as anaemia vs. no anaemia.
Unadjusted analysis includes factors for randomized treatment and history of HF hospitalization and is stratified by diabetes status.
Adjusted analysis includes factors for randomized treatment, history of HF hospitalization, age, heart rate, systolic blood pressure, body mass index, ischaemic aetiology of HF,
left ventricular ejection fraction, NYHA functional class, N-terminal pro-B-type natriuretic peptide, atrial fibrillation, mineralocorticoid receptor antagonist use and estimated
glomerular filtration rate.






































Figure 2 Effect of dapagliflozin compared with placebo on haematocrit according to presence of anaemia. Least square means and 95%
confidence intervals were derived from a mixed-effects model adjusted for baseline values, visit, randomized treatment, and interaction of
treatment and visit with a random intercept and slope per patient.
0.58–0.97) (online supplementary Table S3). The risk of both car-
diovascular death and death from any cause was lower in those
with resolution of anaemia in unadjusted analyses; however, this
was not statistically significant after adjustment for other baseline
variables (online supplementary Table S3). Conversely, the devel-
opment of anaemia was associated with an approximately twofold
increased unadjusted risk of both death from any cause (HR 2.40,
95% CI 1.76–3.28) and the composite endpoint of total (including
recurrent) heart failure hospitalizations and cardiovascular death
(rate ratio 2.02, 95% CI 1.50–2.72).
Adverse events according to baseline
anaemia status
Adverse events and study drug discontinuation were more























.. respective placebo groups) but the rates were not different
between dapagliflozin and placebo in either subgroup (online sup-
plementary Table S4). The rate of stroke did not differ significantly
between treatment arms in the overall DAPA-HF population and
there was no significant interaction between baseline anaemia
status and randomized treatment on the occurrence of stroke
(interaction P = 0.16).
Discussion
In this post-hoc analysis of DAPA-HF we found that anaemia was
common and was associated with worse outcomes, especially
if persistent. Resolution of anaemia was more common with
dapagliflozin than with placebo, and patients who had resolution
of anaemia had better outcomes than those in whom anaemia per-
sisted. The relative risk reductions in the primary and secondary
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. morbidity and mortality endpoints with dapagliflozin, compared
with placebo, were consistent in patients with and without baseline
anaemia. The absolute risk reductions with dapagliflozin in anaemic
individuals were substantial, as a result of the high rates of death
and hospitalization in these patients.
In keeping with prior studies in ambulatory patients, just under a
quarter of patients in DAPA-HF had anaemia.4 These participants
had additional predictors of poor outcome, including older age,
more coronary heart disease and diabetes, lower eGFR and higher
NT-proBNP. Consequently, it was not surprising that anaemic
patients experienced higher rates of death and hospitalization,
as has been documented in many previous reports.4 More novel
was our finding that there was a high rate of anaemia reversal
over time (around 40% in the placebo group) and that the risk
of adverse outcomes associated with persistence of anaemia was
very high, with a more than twofold higher risk of the key
death and hospitalization outcomes examined, compared with
patients exhibiting reversal of anaemia. Together these findings
show that in many patients with HFrEF anaemia is transient
and reversible but that when it persists it is associated with
much poorer outcomes (the relatively higher risk associated with
persisting post-baseline anaemia, compared to baseline anaemia
which resolved, was notable). This finding is in keeping with those
of Tang and colleagues in a study of 6159 consecutive outpatients
with chronic stable heart failure under the care of the Cleveland
Clinic.3
As anticipated, dapagliflozin increased the rate of anaemia cor-
rection (from around 40% to over 60%) and reduced the risk
of development of new anaemia by more than half, although the
mean increase in haematocrit (around 2.4%) was almost identical
in patients with and without anaemia at baseline, demonstrating
that many patients had mild anaemia and a ‘borderline’ baseline
haematocrit.
Dapagliflozin was beneficial in patients without anaemia as well
as in those with anaemia at baseline, although the absolute risk
reductions in hospitalization and death with dapagliflozin were
greater in anaemic individuals, given their higher baseline risk of
these outcomes. There was an absolute reduction of over 7% in
the primary composite endpoint in anaemic patients treated with
dapagliflozin for a median of 18.2 months. Consequently, while
dapagliflozin has large and worthwhile benefits in a broad range
of patients with HFrEF, it may be a particularly useful therapy for
individuals with anaemia because it can correct anaemia, as well as
substantially reduce the elevated risk such patients face.
The much more difficult question to answer is whether cor-
rection of anaemia contributed to the improvement in out-
comes with dapagliflozin. In several modest-sized, short-term,
trials, intravenous iron increased haematocrit and haemoglobin
and improved symptoms, health-related quality of life and func-
tional capacity.7–9 The AFFIRM-AHF trial recently reported a
reduction in the risk of heart failure hospitalization with intra-
venous iron replacement with no significant effect on cardiovascu-
lar death.10 Further ongoing trials will provide more data regarding
the effect of this therapeutic approach. Conversely, while the larger,
longer-term, Reduction of Events With Darbepoetin Alfa in Heart
Failure trial (RED-HF) showed anaemia correction with a synthetic
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Effect of dapagliflozin compared with placebo on cardiovascular outcomes according to anaemia status
Dapagliflozin Placebo Hazard ratio
(95% CI)
Interaction
P-value. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
n/N (%) Rate per 100
person-years
(95% CI)
n/N (%) Rate per 100
person-years
(95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary composite endpoint
Anaemia (n =1032) 97/535 (18.1) 13.2 (10.9–16.2) 125/497 (25.2) 19.4 (16.3–23.1) 0.68 (0.52–0.88) 0.44
No anaemia (n = 3659) 285/1811 (15.7) 11.1 (9.9–12.5) 371/1848 (20.1) 14.6 (13.2–16.2) 0.76 (0.65–0.89)
Cardiovascular death
Anaemia (n =1032) 57/535 (10.7) 7.4 (5.7–9.6) 70/497 (14.1) 10.0 (7.9–12.6) 0.74 (0.52–1.05) 0.48
No anaemia (n = 3659) 169/1811 (9.3) 6.3 (5.4–7.3) 201/1848 (10.9) 7.4 (6.5–8.5) 0.85 (0.70–1.05)
Worsening HF event
Anaemia (n =1032) 65/535 (12.1) 8.9 (7.0–11.3) 90/497 (18.1) 14.0 (11.4–17.2) 0.63 (0.46–0.86) 0.48
No anaemia (n = 3659) 169/1811 (9.3) 6.6 (5.7–7.7) 232/1848 (12.6) 9.1 (8.0–10.4) 0.72 (0.59–0.88)
All-cause mortality
Anaemia (n =1032) 71/535 (13.3) 9.3 (7.3–11.7) 82/497 (16.5) 11.7 (9.4–14.5) 0.78 (0.57–1.08) 0.67
No anaemia (n = 3659) 204/1811 (11.3) 7.6 (6.6–8.7) 244/1848 (13.2) 9.0 (7.9–10.2) 0.85 (0.70–1.02)
Total HF hospitalizations and cardiovascular deatha
Anaemia (n =1032) 151b 19.8 (16.9–23.2) 206b 29.7 (25.9–34.0) 0.66 (0.49–0.89) 0.30
No anaemia (n = 3659) 412b 15.4 (14.0–17.0) 526b 19.5 (17.9–21.2) 0.79 (0.67–0.94)
CI, confidence interval; HF, heart failure.
aRisk estimate presented as rate ratio.
bNumber of events.
erythropoiesis-stimulating agent and improved health-related qual-
ity of life, it did not show a reduction in mortality or morbidity.6
Consequently, to date, there is no other evidence supporting a
contribution of anaemia correction to the reduction in hospitaliza-
tion and death seen with dapagliflozin, although that possibility is
not precluded either, and the means of anaemia correction may be
an important consideration.
Irrespective of the uncertainty about the effect of anaemia
correction on hospitalization and death, treating anaemia does
improve health-related quality of life, and diminished oxygen car-
rying capacity of the blood, limiting the delivery to meet the
metabolic demands of the tissues, is unfavourable in heart fail-
ure. A safe means of correcting anaemia is therefore valuable in
HFrEF. As discussed earlier, the increase in haematocrit observed
with SGLT2i is no longer believed to simply reflect volume con-
traction due to diuresis. Several lines of evidence argue against
volume contraction being the only or even main explanation. Firstly,
the assumption that diuresis increases haematocrit in patients with
heart failure has little support from studies in patients with heart
failure given usual oral doses of conventional diuretics.15,24,25 Sec-
ond, the evidence that SGLT2i have a diuretic and natriuretic action
in heart failure is conflicting and any effect seems to be small
and short-lived.26–28 Moreover, SGLT2i seem to remove interstitial
rather than intravascular fluid.29 Thirdly, as we have reported else-
where, the increase in haematocrit with dapagliflozin was similar in
patients taking or not taking a conventional diuretic and in patients
on larger and smaller doses of diuretic; adding another diuretic
would likely have causes different from changes in volume status in
these various groups.30 The change in haematocrit is also similar in












































.. kidney disease, whereas the glucosuric and diuretic effect of SGLT2i
is different in these different clinical situations.11,31,32 In support of
this, we saw no change in urea after initiation of dapagliflozin; the
rise in creatinine observed is believed to represent a glomerular
haemodynamic action of SGLT2i rather than volume contraction.33
Furthermore, we observed only weak correlations between these,
as well as weight (another potential marker of volume status) and
haematocrit early after randomization (14 days) when any diuretic
effect of dapagliflozin would be greatest, with no evidence of any
correlation at 8 months (with haematocrit continuing to rise from
day 14 to a plateau at 8 months).
Conversely, SGLT2i stimulate erythropoiesis by suppressing hep-
cidin and increasing erythropoietin, although the small physiolog-
ical changes in the latter are quite distinct from the administra-
tion of high-dose exogenous erythropoiesis-stimulating agent as in
RED-HF.6,14–18 A rise in reticulocyte count preceding the rise in
haematocrit supports true augmentation of haematopoiesis.15 An
increase in endogenous erythropoietin production is an attractive
potential mechanism of action in HFrEF as blunted erythropoi-
etin production has been identified as a contributor to anaemia
in heart failure.4 Clearly, erythropoietin stimulated haematopoiesis
raises questions about iron sufficiency, given the high prevalence
of iron deficiency in HFrEF, and in one study increased erythro-
poietin production in response to SGLT2i was associated with
a decrease in serum ferritin levels.34 These observations suggest
that further investigation of the effects of SGLT2i on iron uti-
lization and other factors involved in erythropoiesis is warranted
in anaemic HFrEF patients.4,7–10 The potential limitation of ery-
thropoietic response in such patients without concomitant iron
replenishment also raises the potential for a therapeutic synergy
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. between intravenous iron and SGLT2 inhibition in some patients
with HFrEF and highlights one potential explanation for why some
patients in the present trial did not have correction of anaemia with
dapagliflozin.
Finally, it is worth noting that the increase in haematocrit
and haemoglobin with SGLT2 inhibition contrasts with the
decrease caused by renin–angiotensin system blockers, especially
angiotensin-converting enzyme inhibitors and carvedilol.1,35
Limitations
As with all studies of this nature there are inherent limitations.
Analysis of anaemia was not pre-specified. Erythropoietin, hepcidin,
ferritin, red cell mass and reticulocyte count were not measured in
DAPA-HF. We did not have serial measurements of haemoglobin
as well as haematocrit. We cannot exclude the possibility that
some, or all, of the increase in haematocrit observed was due to
reduction in plasma volume, although conventional diuretics gen-
erally do not increase haematocrit or haemoglobin.18 Dapagliflozin
improved survival compared with placebo, therefore there may be
an element of survivor bias in the analysis where patients random-
ized to dapagliflozin were more likely to be alive, to be able to
provide measurements of haematocrit and therefore experience
correction of anaemia.
Conclusions
In conclusion, in patients with HFrEF in DAPA-HF, those with
anaemia had worse outcomes. Dapagliflozin corrected anaemia
more often than placebo and improved outcomes, irrespective of
anaemia status at baseline.
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